Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 26, 2016
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - July 26, 2016

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/25/16 - "Antitumor Agent and Antitumor Effect Enhancer" in Patent Application Approval Process (USPTO 20160193241)
It is known that antitumor effect of FTD is enhanced by TPI that suppresses in vivo decomposition of FTD by thymidine phosphorylase. Currently, an antitumor agent containing FTD and TPI at a molar ratio of 1: 0.5 is under development as a therapeutic agent for a solid cancer such as colorectal cancer. "Furthermore, combination therapies to enhance
7/25/16 - "Substituted Heterocycle Fused Gamma-Carbolines Solid" in Patent Application Approval Process (USPTO 20160194325)
By a News Reporter-Staff News Editor at Mental Health Weekly Digest A patent application by the inventors TOMESCH, John; WENNOGLE, Lawrence P., filed on November 30, 2015, was made available online on July 14, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. "These compounds are disclosed in WO 2000/
7/25/16 - Abbott Laboratories Files SEC Form 425, Prospectuses And Communications, Business Combinations (Jul. 12, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on July 12, 2016. The SEC file number is 0001104659-16-132244.. A U.S. Securities and Exchange Commission filing is a
7/25/16 - Abbott Laboratories Files SEC Form 8-K, Current Report (Jul. 12, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on July 12, 2016. The SEC file number is 0001104659-16-132243.. A U.S. Securities and Exchange Commission filing is a
7/25/16 - AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen
NORTH CHICAGO, Ill.& NEW YORK AbbVie and Bristol-Myers Squibb Company today announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie s investigational biomarker-specific antibody drug conjugate Rova-T in combination with Bristol-Myers Squibb s Opdivo and Opdivo+ Yervoy regimen as a treatment for
7/25/16 - AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR? (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
AbbVie, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration has approved a New Drug Application for VIEKIRA XR? extended-release tablets. "AbbVie's work continues to contribute to the transformation of hepatitis C care through our focus on evolving our current therapies as part of our ongoing commitme
7/25/16 - Acadia Pharmaceuticals Inc. Files SEC Form SC 13G/A, Statement of Acquisition of Beneficial Ownership By Individuals (Jul. 8, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acadia Pharmaceuticals Inc. was posted on July 8, 2016. The SEC file number is 0000215457-16-006408.. A U.S. Securities and Exchange Commission filin
7/25/16 - Acceleron Pharma Appoints Thomas McCourt to its Board of Directors
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body s ability to rebuild and repair its own cells and tissues, today announced the appointment of the experienced commercial executive, Thomas McCourt, to its Board of Directors, effective...
7/25/16 - Acceleron Pharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jul. 7, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on July 7, 2016. The SEC file number is 0001179110-16-027530.. A U.S. Securities and Exchange Commission filing is a
7/25/16 - Acceleron Pharma Inc. Files SEC Form 8-K, Current Report (Jul. 11, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on July 11, 2016. The SEC file number is 0001280600-16-000094.. A U.S. Securities and Exchange Commission filing is
7/25/16 - Acelrx Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Jul. 8, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acelrx Pharmaceuticals Inc. was posted on July 8, 2016. The SEC file number is 0001437749-16-035024.. A U.S. Securities and Exchange Commission filin
7/25/16 - Achaogen Inc. Files SEC Form 424B3, Prospectus [Rule 424(B)(3)] (Jul. 12, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achaogen Inc. was posted on July 12, 2016. The SEC file number is 0001301501-16-000077.. A U.S. Securities and Exchange Commission filing is a formal
7/25/16 - Achaogen Inc. Files SEC Form CT ORDER, Confidential Treatment Order (Jul. 7, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achaogen Inc. was posted on July 7, 2016. The SEC file number is 9999999997-16-024307.. A U.S. Securities and Exchange Commission filing is a formal
7/25/16 - Achaogen Inc. Files SEC Form EFFECT, Notice of Effectiveness (Jul. 12, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achaogen Inc. was posted on July 12, 2016. The SEC file number is. A U.S. Securities and Exchange Commission filing is a formal document or financial
7/25/16 - Aclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis (SK); Provides Update on Clinical Programs
Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, today announced the completion of patient enrollment in its two Phase 3 pivotal clinical trials and its Phase 3 open-label safety trial of its lead candidate, A-101 Topical Solution for the treatment of seborrheic keratosis. A-101 is a proprietary high-concentration...
7/25/16 - Aclaris Therapeutics, Inc. (Nasdaq: ACRS) to Ring The Nasdaq Stock Market Closing Bell
What: Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, will visit the Nasdaq MarketSite in Times Square. Where: Nasdaq MarketSite 4 Times Square 43 rd& Broadway Broadcast Studio. Gal 3 C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/ 4 SR 13.235 DR 18.295411 MOD 4: 2: 0 DVBS QPSK.
7/25/16 - Actinium Pharmaceuticals, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jul. 7, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Actinium Pharmaceuticals, Inc. was posted on July 7, 2016. The SEC file number is 0000921895-16-005107.. A U.S. Securities and Exchange Commission fi
7/25/16 - Actinium Receives Assignment of Intellectual Property From Memorial Sloan Kettering Cancer Center Specific to Actinium's APIT Platform and the Use of...
By a News Reporter-Staff News Editor at Pharma Business Week Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the Company has been assigned two provisional patent applications from Memorial Sloan-Kettering Cancer Center.
7/25/16 - Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced top-line 24- week data demonstrating persistent migraine prevention in a Phase 2 b clinical trial evaluating ALD403 in patients with chronic migraine. In March 2016, Alder reported that the Phase 2 b study met bo
7/25/16 - Alexza Pharmaceuticals Inc. Files SEC Form EFFECT, Notice of Effectiveness (Jul. 8, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alexza Pharmaceuticals Inc. was posted on July 8, 2016. The SEC file number is. A U.S. Securities and Exchange Commission filing is a formal document
7/25/16 - Alimera Sciences Inc. Files SEC Form 8-K, Current Report (Jul. 12, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alimera Sciences Inc. was posted on July 12, 2016. The SEC file number is 0001267602-16-000151.. A U.S. Securities and Exchange Commission filing is
7/25/16 - Allergan Receives Positive Opinion For Truberzi (Eluxadoline) For Treatment Of Irritable Bowel Syndrome With Diarrhoea (IBS-D) In Adults
Allergan plc, a leading global pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use has adopted a Positive Opinion for TRUBERZI in the European Union. 4 TRUBERZI is an oral medication that relieves the main symptoms of irritable bowel syndrome with diarrhoea in adults. 1 In two pivotal trials, TRUB
7/25/16 - Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its ongoing Phase 1 study with fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B and rare bleeding disorders. These new data will be presented in an oral presentation at the Worl
7/25/16 - Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia (WFH) 2016 World Congress
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that Alnylam and collaborators will present interim results from the ongoing Phase 1 clinical trial with fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B and rare bleeding disorders at the World Federati
7/25/16 - Amicus Therapeutics Inc. Files SEC Form 8-K, Current Report (Jul. 11, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Amicus Therapeutics Inc. was posted on July 11, 2016. The SEC file number is 0001104659-16-131924.. A U.S. Securities and Exchange Commission filing
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415